RU2669565C2 - Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения - Google Patents

Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения Download PDF

Info

Publication number
RU2669565C2
RU2669565C2 RU2014142025A RU2014142025A RU2669565C2 RU 2669565 C2 RU2669565 C2 RU 2669565C2 RU 2014142025 A RU2014142025 A RU 2014142025A RU 2014142025 A RU2014142025 A RU 2014142025A RU 2669565 C2 RU2669565 C2 RU 2669565C2
Authority
RU
Russia
Prior art keywords
release
analgesic
pharmaceutical composition
hours
lps
Prior art date
Application number
RU2014142025A
Other languages
English (en)
Russian (ru)
Other versions
RU2014142025A (ru
Inventor
Дэвид А. ДИЛЛ
Original Assignee
УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of RU2014142025A publication Critical patent/RU2014142025A/ru
Application granted granted Critical
Publication of RU2669565C2 publication Critical patent/RU2669565C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014142025A 2012-03-19 2013-03-13 Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения RU2669565C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/424,000 2012-03-19
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 2012-06-04
PCT/US2013/030901 WO2013142197A1 (fr) 2012-03-19 2013-03-13 Formulation à libération prolongée pour réduire la fréquence de miction et son procédé d'utilisation

Publications (2)

Publication Number Publication Date
RU2014142025A RU2014142025A (ru) 2016-05-10
RU2669565C2 true RU2669565C2 (ru) 2018-10-12

Family

ID=49223209

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2014142025A RU2669565C2 (ru) 2012-03-19 2013-03-13 Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения
RU2014142066/15A RU2599017C2 (ru) 2012-03-19 2013-03-14 Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения
RU2016133305A RU2016133305A (ru) 2012-03-19 2013-03-14 Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения

Family Applications After (2)

Application Number Title Priority Date Filing Date
RU2014142066/15A RU2599017C2 (ru) 2012-03-19 2013-03-14 Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения
RU2016133305A RU2016133305A (ru) 2012-03-19 2013-03-14 Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения

Country Status (15)

Country Link
EP (2) EP2827852A4 (fr)
JP (5) JP2015510928A (fr)
KR (4) KR20140134333A (fr)
CN (4) CN107157991A (fr)
AU (4) AU2013235518B2 (fr)
BR (2) BR112014020271A8 (fr)
CA (2) CA2866853A1 (fr)
HK (3) HK1251469A1 (fr)
MX (3) MX2014011128A (fr)
MY (2) MY174090A (fr)
NZ (6) NZ714288A (fr)
RU (3) RU2669565C2 (fr)
SG (2) SG11201500408VA (fr)
WO (2) WO2013142197A1 (fr)
ZA (2) ZA201405862B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
JP2017516832A (ja) * 2014-06-06 2017-06-22 ウェルズリー ファーマスーティカルズ、エルエルシー 排尿頻度を減少させるための医薬製剤およびその使用の方法
KR101809908B1 (ko) * 2014-07-21 2018-01-25 주식회사 종근당 5-알파환원효소억제제를 포함하는 조성물
ES2923438T3 (es) * 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico
EP3355864A4 (fr) * 2015-09-30 2019-05-22 Wellesley Pharmaceuticals, LLC Composition pour réduire la fréquence de la miction, procédé de fabrication et d'utilisation de celle-ci
WO2017058436A1 (fr) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition pour réduire la fréquence de la miction, procédé de fabrication et d'utilisation de celle-ci
CN105238124B (zh) * 2015-11-16 2018-02-09 太仓东能环保设备有限公司 一种抗菌腻子粉
JP6294924B2 (ja) 2016-09-05 2018-03-14 株式会社Ｓｕｂａｒｕ 車両の走行制御装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2307651C2 (ru) * 2001-04-05 2007-10-10 Тиога Фармасьютиклз, Инк. Каппа-опиатные агонисты для лечения заболеваний мочевого пузыря
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2546399A (en) * 1998-02-10 1999-08-30 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
EP1476146A1 (fr) * 2002-02-19 2004-11-17 Pharmacia Corporation Utilisation d'inhibiteurs de la cyclooxygenase et d'agents anti-muscariniques destinee au traitement de l'incontinence
IL165370A0 (en) * 2002-06-07 2006-01-15 Astellas Pharma Inc Therapeutic agent for overactive bladder
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
CN1758904A (zh) * 2003-03-21 2006-04-12 麦克内尔-Ppc股份有限公司 非甾体抗炎药物的给药方案
JP2006520799A (ja) * 2003-03-21 2006-09-14 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 平滑筋調節因子およびα２δサブユニットカルシウムチャネル調節因子を用いた、下部尿路障害を処置するための方法
EP1627876A1 (fr) * 2004-08-20 2006-02-22 Ferring B.V. Composés hétérocycliques condensés et leur usage et leur utilisation comme anti-diurétiques
EP2400300A1 (fr) * 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Procédé de sélection d'agents préventifs/remèdes pour l'incontinence de stress
TW200716140A (en) * 2005-06-17 2007-05-01 Dynamis Therapeutics Inc Treatment of inflammatory conditions
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
ATE506059T1 (de) * 2005-09-02 2011-05-15 Theravida Inc Therapie zur behandlung der überaktiven blase
US20120064159A1 (en) * 2009-05-28 2012-03-15 Aptapharma, Inc. Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20120244221A1 (en) * 2010-07-08 2012-09-27 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2307651C2 (ru) * 2001-04-05 2007-10-10 Тиога Фармасьютиклз, Инк. Каппа-опиатные агонисты для лечения заболеваний мочевого пузыря
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SAITO M. et al. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience// Int J Urol. 2004 Aug;11(8):592-6. *
SONG Y.S. et al. Zolpidem pharmacotherapy combined with alpha-blocker therapy for nocturia unresponsive to alpha-blocker monotherapy in men with lower urinary tract symptoms: a preliminary study// Int Urol Nephrol. 2007; 39(4): 1147-52, abstract. *
ЛОПАТКИН Н.А. под ред. "Урология"// М., "ГЭОТАР-Медиа", 2002, с.216, абзац 3. DUTHIE J.B. et al. Botulinum toxin injections for adults with overactive bladder syndrome// Cochrane Database Syst Rev. 2011, Dec 7;(12): CD005493. *
ЛОПАТКИН Н.А. под ред. "Урология"// М., "ГЭОТАР-Медиа", 2002, с.216, абзац 3. DUTHIE J.B. et al. Botulinum toxin injections for adults with overactive bladder syndrome// Cochrane Database Syst Rev. 2011, Dec 7;(12): CD005493. SAITO M. et al. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience// Int J Urol. 2004 Aug;11(8):592-6. *

Also Published As

Publication number Publication date
AU2013235518A1 (en) 2014-09-25
RU2016133305A3 (fr) 2018-12-10
JP2015510936A (ja) 2015-04-13
MX2014011129A (es) 2015-08-10
AU2013235507A1 (en) 2014-08-21
AU2017203246B2 (en) 2018-10-18
MY174090A (en) 2020-03-09
AU2013235518A2 (en) 2014-10-09
CN104302284A (zh) 2015-01-21
JP2015510928A (ja) 2015-04-13
RU2014142066A (ru) 2016-05-10
EP2827852A1 (fr) 2015-01-28
WO2013142274A1 (fr) 2013-09-26
MX2019008817A (es) 2019-09-26
CN107157991A (zh) 2017-09-15
EP2827852A4 (fr) 2016-03-02
NZ630471A (en) 2016-04-29
KR20140134284A (ko) 2014-11-21
BR112014020113A2 (fr) 2017-06-20
RU2599017C2 (ru) 2016-10-10
CN107789626A (zh) 2018-03-13
HK1243921A1 (zh) 2018-07-27
NZ714288A (en) 2016-12-23
CA2866853A1 (fr) 2013-07-26
JP2018024693A (ja) 2018-02-15
NZ714662A (en) 2016-08-26
AU2017203139B2 (en) 2018-07-19
ZA201406146B (en) 2016-08-31
MY175764A (en) 2020-07-08
SG11201500409SA (en) 2015-03-30
RU2016133305A (ru) 2018-12-10
MX2014011128A (es) 2015-08-10
JP2016172752A (ja) 2016-09-29
AU2017203139A1 (en) 2017-06-01
BR112014020113A8 (pt) 2017-07-11
EP2827851A4 (fr) 2015-10-14
KR20170015537A (ko) 2017-02-08
NZ628079A (en) 2016-05-27
AU2017203246A1 (en) 2017-06-08
WO2013142197A1 (fr) 2013-09-26
BR112014020271A2 (fr) 2017-06-20
NZ718163A (en) 2017-09-29
HK1251469A1 (zh) 2019-02-01
HK1204553A1 (en) 2015-11-27
KR20140134333A (ko) 2014-11-21
JP2018138602A (ja) 2018-09-06
CA2866755A1 (fr) 2013-09-26
KR20190003840A (ko) 2019-01-09
NZ712594A (en) 2016-09-30
AU2013235518B2 (en) 2017-03-02
EP2827851A1 (fr) 2015-01-28
RU2014142025A (ru) 2016-05-10
AU2013235507B2 (en) 2017-03-23
BR112014020271A8 (pt) 2017-07-11
SG11201500408VA (en) 2015-03-30
CN104321056A (zh) 2015-01-28
ZA201405862B (en) 2016-08-31

Similar Documents

Publication Publication Date Title
US20130196012A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
RU2669565C2 (ru) Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения
RU2603471C2 (ru) Состав с замедленным высвобождением для снижения частоты мочеиспускания и способ его применения
US20180344674A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US20170319579A1 (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20180055858A1 (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
US10792261B2 (en) Extended, delayed and immediate release formulation method of manufacturing and use thereof
US20170100413A1 (en) Composition for reducing the frequency of urination, method of making and use thereof
AU2016331871A1 (en) Composition for reducing the frequency of urination, method of making and use thereof
US10596127B2 (en) Composition for reducing the frequency of urination, method of making and use thereof
EP2612663A1 (fr) Formulation à libération prolongée pour réduire la fréquence de la miction et son procédé dýutilisation
US20170079964A1 (en) Composition for reducing the frequency of urination, method of making and use thereof
EP3355877A1 (fr) Composition pour réduire la fréquence de la miction, procédé de fabrication et d'utilisation de celle-ci

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200314